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ABSTRACT
Introduction: Androgen deprivation therapy
(ADT) is a mainstay of treatment against
advanced prostate cancer (PC). As a treatment
goal, suppression of plasma testosterone levels
to\50 ng/dl has been established over decades.
Evidence is growing though that suppression to
even lower levels may add further clinical
benefit. Therefore, we undertook a pooled
retrospective analysis on the efficacy of 1-, 3-,
and 6-month sustained-release (SR)
formulations of the gonadotropin-releasing
hormone (GnRH) agonist triptorelin to
suppress serum testosterone concentrations
beyond current standards.
Methods: Data of 920 male patients with PC
enrolled in 9 prospective studies using
testosterone serum concentrations as primary
endpoint were pooled. Patients aged
42–96 years had to be eligible for ADT and to
be either naı¨ve to hormonal treatment or have
undergone appropriate washout prior to
enrolment. Patients were treated with
triptorelin SR formulations for 2–12 months.
Primary endpoints of this analysis were serum
testosterone concentrations under treatment
and success rates overall and per formulation,
based on a testosterone target threshold of
20 ng/dl.
Results: After 1, 3, 6, 9, and 12 months of
treatment, 79%, 92%, 93%, 90%, and 91% of
patients reached testosterone levels \20 ng/dl,
respectively. For the 1-, 3-, and 6-month
formulations success rates ranged from
80–92%, from 83–93%, and from 65–97% with
median (interquartile range) serum testosterone
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values of 2.9 (2.9–6.5), 5.0 (2.9–8.7), and 8.7
(5.8–14.1) ng/dl at study end, respectively.
Conclusion: In the large majority of patients,
triptorelin SR formulations suppressed serum
testosterone concentrations to even\20 ng/dl.
Testosterone should be routinely monitored in
PC patients on ADT although further studies on
the clinical benefit of very low testosterone
levels and the target concentrations are still
warranted.
Keywords: Advanced prostate cancer;
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INTRODUCTION
Based on recent estimates, prostate cancer (PC)
ranks first among all new male cancers in both
the USA and Europe (21% in 2016 and 22.8% in
2012, respectively) [1, 2]. Testosterone is known
to foster PC cell growth; thus, the backbone
therapy of advanced PC is androgen deprivation
(ADT). Approximately 90% of tumours respond
to initial ADT, which may result in a marked
symptom reduction and prolonged survival,
even if androgen-independent disease
eventually develops [3–5].
ADT was initially achieved surgically via
bilateral orchiectomy. Gonadotropin-releasing
hormone (GnRH) analogues emerging in the
1980s offered a novel approach to medical
castration through suppression of the
hypothalamic-pituitary-gonadal axis. One of
these was triptorelin, which was shown to be
up to 100 times more potent than the native
GnRH in vitro and in vivo [6–8]. Its clinical
development started in 1982 [3] and it was
registered as the first GnRH agonist SR
formulation worldwide in France in 1986.
Today, GnRH agonists are used worldwide for
ADT [9] with survival rates similar to surgical
castration [10]. They reduce serum testosterone
to castrate levels via the decrease in pituitary
gonadotropin secretion that follows
down-regulation of the pituitary GnRH
receptors [11]. The ensuing hypoandrogenic
environment results in glandular and tumour
shrinkage and in an increase of interglandular
connective tissue [4, 12, 13].
A testosterone level of 50 ng/dl (1.7 nmol/l)
has been established as the standard castration
threshold, which has been applied for over
40 years [14]. This threshold is widely accepted
by regulatory authorities for the approval of
GnRH analogues in the treatment of advanced
PC [14, 15] and is also deemed adequate by the
National Comprehensive Cancer Network
(NCCN) [16]. The European Association of
Urology (EAU) indeed also acknowledges the
50 ng/dl cut-off, but suggests 20 ng/dl
(0.7 nmol/l) to be more appropriate as ‘‘better
results are repeatedly observed with lower levels
compared to 50 ng/dl’’ [17].
In fact, there is growing evidence that the
extent of testosterone suppression during ADT
in hormone-sensitive PC patients predicts a
lower risk of and shorter time to
androgen-independent progression or
castration-resistant PC (CRPC), although so far
most studies have been retrospective and
sample sizes were rather small [4, 11,
14, 18–20]. Advances in the understanding of
the principal mechanisms of PC progression
and resistance to castration have led to new
agents for CRPC such as the testosterone
synthesis inhibitor abiraterone and the
androgen receptor blocker enzalutamide. The
improved survival in patients with metastatic
CRPC when adding these agents to first-line
ADT with GnRH analogues (or surgical
castration) also indicates an important role of
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low testosterone levels in the treatment of
advanced PC [21, 22].
Efficacy results of triptorelin 1-, 3-, and
6-month formulations in patients with
advanced PC have been published based on
the standard castration limit of serum
testosterone of 50 ng/dl. Reports suggesting
that serum testosterone levels below this
standard threshold might lead to improved
clinical outcomes [4, 11, 14, 18–20] prompted
us to re-examine testosterone data from nine
phase II to IV studies, which is so far the largest
analysis examining the efficacy of ADT at a
cut-off level of 20 ng/dl [3, 9, 23].
METHODS
This is a retrospective pooled analysis of nine
prospective clinical studies on the efficacy of
triptorelin 1-, 3-, and 6-month SR formulations
for advanced PC with overall 920 evaluable
patients. Four studies were randomised
controlled phase II studies, two were
randomised controlled phase III studies, and
three were non-controlled phase II to IV studies
(Table 1). Primary endpoints always included
testosterone assessments measured by either
validated radioimmunoassay (RIA) or liquid
chromatography tandem mass spectrometry
(LC-MS/MS) [3, 9, 24, 25], which proved to
show comparable results at both high and low
testosterone concentrations. At the very low
levels expected in men under ADT, RIA and
LC–MS/MS are considered the most accurate
and reliable methods.
Patients were recruited in Europe and South
Africa and had to have an indication for ADT,
i.e., advanced or metastatic PC or rising
prostate-specific antigen (PSA) after failed
local therapy, were naı¨ve to hormonal
treatment or had undergone a 6-month
washout period prior to study treatment, and
presented with a normal baseline testosterone
level at study entry. None of the patients
except those in study E28-52014-701
(flutamide for 10 days) received any ADT.
Concomitant treatments affecting the
metabolism or secretion of testosterone were
prohibited in all studies. Patients were treated
with only one of the triptorelin formulations
and investigated for 2–12 months (Fig. S1)
except in study E28-52014-701 in which some
patients were switched from the 1-month to
the 3-month formulation (Table 1). All
procedures performed in the original studies
were in accordance with the ethical standards
of institutional and national research
committees and with the 1964 Helsinki
Declaration and its later amendments or
comparable ethical standards. Informed
consent was obtained from all patients
enrolled in the original studies; for the
retrospective pooled analysis no formal
consent is required.
Descriptive statistics were used to present
demographic data, testosterone concentrations,
and success rates. For the calculation of mean
testosterone levels over various ranges of
months, first the mean value for all available
measurements over the indicated range of
months was calculated for each patient
without imputation for missing values, and
then the mean and standard error (SE) for
each group were calculated based on these
means. For the comparison of baseline
characteristics, Student’s t test and chi-square
test were used. Data pooling and data
management were done in SAS (version 9.4)
and MS Access 2013. Analyses were performed
and figures created with R Core Team (2016).
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RESULTS
Mean age was similar among formulation
groups with ages ranging from 42 to 96 years.
Overall, half of the patients were Caucasian and
one quarter black (Table 2). The 6-month
formulation group had significantly higher
testosterone levels as compared to the other
two groups at baseline, i.e., means (95% CIs):
358.6 (345.8; 371.4) ng/dl in the 1-month
formulation group and 383.1 (363.5; 402.7)
ng/dl in the 3-month formulation as
compared to 502.6 (467.4; 537.8) ng/dl in the
6-month formulation group (Table 2). The
mean BMI was also higher in the 6-month
formulation group as compared to the others.
The pooled data of all studies showed that a
high proportion of patients achieved a
testosterone level\20 ng/dl at the time points
pre-defined in the protocols (i.e., months 1, 3,
6, 9, and 12), regardless of the formulation.
Overall success rates based on the castration
limit of 20 ng/dl reached 79% (95% CI:
75.9–81.3%) at month 1, 92% (89.7–93.6%) at
month 3, 93% (90.4–94.4%) at month 6; 90%
(87.2–92.0%) at month 9, and 91%
(84.6–95.8%) at month 12. The success rates
based on the standard castration limit of 50 ng/dl
ranged from 95–99% (Fig. 1).
Overall, mean testosterone levels were
maintained\20 ng/dl over study periods for
all formulations except for the 6-month
formulation at months 1 and 12 (Fig. 2)
because of single patients with exceptionally
high levels (patient DEB-TRI6M-301-11-11613
with a value 422 ng/dl at month 1 and patient
DEB-TRI6M-301-04-04602 with a value of
1213 ng/dl at month 12). Excluding those as
outliers would result in mean values of 18.5 and
13.1 ng/dl, respectively.
Success rates per formulation in terms of the
proportion of patients with
testosterone\20 ng/dl ranged from 80–92%
for the 1-month formulation, 83–93% for the
3-month formulation, and 65–97% for the
6-month formulation (Fig. 1b). The large
majority of patients (89.7%) maintained
stable low testosterone levels without two
Table 2 Demographic data and baseline characteristics, means (range) or n (%)
Triptorelin formulation 1 month (3.75 mg) 3 month (11.25 mg) 6 month (22.5 mg) All
Patients enrolled 489 303 128 920
Age (years) 71.1 (42–96) 70.5 (48–93) 71.1 (51–93) 70.9 (42–96)
Weight (kg) 74.2 (40–129) 74.6 (38–132) 83.3 (47–136) 75.8 (38–136)
BMI (kg/m2) 24.8 (13–43) 25.2 (16–44) 27.6 (19–42) 25.4 (13–44)
Testosterone (ng/dl) 358.6 (3–1015) 383.1 (40–1296) 502.6 (54–1171) 386.7 (3–1296)
Racea, n (%) 421 (100) 240 (100) 128 (100) 789 (100)
Caucasian 231 (54.9) 147 (61.2) 85 (66.4) 463 (58.7)
Black 128 (30.4) 65 (27.1) 27 (21.1) 220 (27.9)
Coloured 61 (14.5) 27 (11.3) 16 (12.5) 104 (13.2)
Other 1 (0.2) 1 (0.4) 0 (0) 2 (0.2)
BMI body mass index
a Data on ethnicity were not collected in study E28-52014-701
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consecutive increases in serum testosterone
to C20 ng/dl. Only very few patients (1.1%)
experienced such testosterone escapes
to C50 ng/dl. Pooling data from all
formulations resulted in mean testosterone
levels just above 10 ng/dl for months 1–6, 1–9,
and 1–12. Testosterone still decreased between
months 1 and 2 and mean values were\10 ng/
Fig. 1 a Proportion of patients achieving a testosterone
level\20 or\50 ng/dl at months 1, 3, 6, 9, and 12 after
treatment with any triptorelin formulation. b Proportion
of patients achieving a testosterone level\20 ng/dl overall
and per each formulation (TRI1M: 1-month; TRI3M:
3-month; TRI6M: 6-month, the only formulation with
12-month data available). Tick marks indicate the exact
95% CI. N number of patients with testosterone data
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dl for months 2–6, 2–9, and 2–12 (Fig. S2). At
the end of the studies, median (IQR) serum
testosterone values were 2.9 (2.9–6.5) ng/dl for
the 1-month formulation, 5.0 (2.9–8.7) ng/dl
for the 3-month formulation, and 8.7 (5.8–14.1)
ng/dl for the 6-month formulation.
DISCUSSION
Our analysis of pooled testosterone data was
based on a total of almost 1000 patients and is,
so far, the largest of its kind. The great majority
of patients treated with triptorelin were shown
to achieve and maintain testosterone levels
\20 ng/dl. This is in line with two other
retrospective studies reassessing testosterone
levels achieved by either orchiectomy [14] or
by use of polymer-delivered subcutaneous
leuprolide acetate formulations [26].
Suppression of testosterone levels\20 ng/dl
through ADT may thus be common and
regardless of the formulation, although in our
study, the testosterone decrease with the
6-month formulation appeared less rapid.
However, this might have been due to a
slightly different patient population as
reflected by higher baseline BMI and
testosterone levels. In fact, obese patients were
reported to respond less to GnRH agonist
treatment as compared to patients with
normal BMI [27]. By contrast, the efficacy of
the triptorelin 6-month formulation has
recently been confirmed by a Danish study
with patients under triptorelin showing
significantly lower testosterone levels at
months 3 and 6 than after subcapsular
orchiectomy [28].
Still, some limitations of our study may
need to be considered: Safety data of the nine
studies were not pooled and re-analysed as the
overall safety profile of triptorelin treatment in
PC has recently been confirmed to be
well-established and consistent among
formulations as well [29]. A more relevant
limitation might be inherent to the
retrospective design. Although all included
clinical trials were quite homogeneous in
terms of design, quality, enrolled populations,
and analytical methods for the measurement
of testosterone, they were of rather short
Fig. 2 Mean serum testosterone levels (ng/dl) versus
selected time points (months) for each and all
formulations—partly zoomed scale. The time values for
the different formulations (all, TRI1M: 1-month, TRI3M:
3-month, and TRI6M: 6-month formulation) are slightly
offset to distinguish the corresponding measurements for
each formulation
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duration and did therefore not allow for an
assessment of the time to androgen-
independent progression (AIP) or death. Thus,
the clinical benefit of achieving testosterone
levels\20 ng/dl could actually not be
addressed. However, evidence is growing that
such a benefit indeed exists, even though most
studies so far have been retrospective as well
and rather small in size.
In 73 PC patients on ADT followed up
for 51 months (range 1–20 years) the lowest
serum testosterone cut-off that was able to
discriminate regarding AIP-free survival was
32 ng/dl (88 vs. 137 months; P\0.03).
However, only breakthrough testosterone
increases[50, but not[20 ng/dl had a
significant impact on AIP-free survival [18]. In
225 Japanese PC patients treated with combined
androgen blockade and followed up for
45.8 months, multivariate analysis revealed
nadir testosterone\20 ng/dl to be the most
significant prognostic factor of overall survival
[20]. The risk of death was also shown to
significantly correlate with 6-month serum
testosterone levels in 129 patients with
metastatic PC treated with goserelin and
followed up for 47.5 months (range 22–72)
[11]. In the largest and longest retrospective
study so far with 626 PC patients having
received ADT for a median of 8 years, nadir
testosterone levels\20 ng/dl were shown to be
associated with longer times to disease
progression [30]. Conversely, patients with a
median testosterone level[20 ng/dl had a
significantly higher risk of developing CRPC.
Maximum testosterone levels C50 ng/dl (23% of
patients) were associated with a significantly
higher rate of progression to CRPC as
compared to patients with maximum
testosterone\20 ng/dl (27%) and patients with
nadir testosterone levels C50 ng/dl (1%) had a
significantly higher risk of dying from disease as
compared to patients with nadir testosterone
20–50 (21%) and\20 ng/dl (78%).
By contrast, there have been only two
prospective studies on the additional benefit of
suppressing testosterone to lower serum
thresholds or minimum levels: In 32 patients
followed up for about 2 years, time to CRPC was
significantly longer in those with 9-month
testosterone\32 ng/dl as compared to those
with[32 ng/dl; however no additional
predictive value was found for those\20 ng/dl
[4]. In the second study, 153 patients with
advanced PC were treated with GnRH agonists
for 65 months. Testosterone levels\20 ng/dl
after 6 months were found to be associated
with a significantly lower risk of death and a
trend towards a lower risk of disease progression
(P = 0.12) as compared to those[20 ng/dl [19].
In conclusion, evidence is growing that
sustainable testosterone suppression\20 ng/dl
is beneficial in patients with PC. Reassuringly,
this is widely achieved with all triptorelin SR
formulations. Still, regular assessment of
testosterone levels should be routine clinical
practice for men on ADT and patients who
under GnRH therapy do not succeed in
achieving an appropriate testosterone
suppression may qualify for an alternative
method of ADT. Well-designed and sufficiently
powered prospective studies using accurate and
reliable testosterone assays are warranted to
further evaluate the clinical benefit of a more
rigorous testosterone suppression to minimum
levels and to establish a new target threshold for
testosterone levels.
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